Join to view full profile
1275 York AvenueNew York, NY 10065
Phone+1 347-798-9896
Dr. Sawyers is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of California (San Francisco)Residency, Internal Medicine, 1985 - 1988
Johns Hopkins University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1986 - Present
NY State Medical License 2006 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2008
- Elected Member The American Society for Clinical Investigation, 1999
- Investigator Howard Hughes Medical Institute
Clinical Trials
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
- Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Publications & Presentations
PubMed
- Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.Jia J Li, Alessandro Vasciaveo, Dimitris Karagiannis, Zhen Sun, Kristjan H Gretarsson
Nature. 2026-06-30 - Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.Justin Jee, Jiajia Zhang, Jessica A Lavery, Michele Waters, Christoper J Fong
Cancer Discovery. 2026-06-22 - Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.Samir Zaidi, Maren Büttner, Weiran Feng, Caitlin Baxter, D Henry Kates
Biorxiv. 2026-05-08
Journal Articles
- Strategies to Identify and Target Cells of Origin in Prostate CancerCharles Sawyers, MD, Journal of the National Cancer Institute
Authored Content
- Tumor Copy Number Alteration Burden Is a Pan-Cancer Prognostic Factor Associated with Recurrence and DeathSeptember 2018
Press Mentions
September 4, 2025: Key Research Breakthroughs from MSKSeptember 4th, 2025- Office Hours Getting to Know… Ping MuApril 1st, 2025
- Annual Meeting 2022: Opening Plenary Showcases Cutting-Edge Scientific ProgramMay 3rd, 2022
Grant Support
- Leveraging Observational (Real World) Data to Advance Precision OncologySLOAN-KETTERING INST CAN RESEARCH2024–2029
- Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceSLOAN-KETTERING INST CAN RESEARCH2015–2025
- Understanding Resistance To Next Generation AntiandrogensNational Cancer Institute2012
- Translational Research In Oncology Training ProgramNational Cancer Institute2011
- Akt-Independent Pathways Of Phosphoinositide 3-Kinase Dependent TransformationNational Cancer Institute2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
